Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067974 | 0.86 | TSHR (0.53) | NCEH1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL15498949 | 0.85 | P4HB (0.39) | P4HBNCEH1ALDH1A1KDM4CMAPT | |
| SCHEMBL27001691 | 0.83 | ACHE (0.54) | NCEH1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL19719018 | 0.82 | ELANE (0.42) | P4HBNCEH1TRPV4TMPRSS4 | |
| SCHEMBL23614061 | 0.81 | TNFSF11 (0.50) | NCEH1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL11673708 | 0.81 | TSHR (0.57) | ALDH1A1KDM4EGAATSHRRAB9A | |
| SCHEMBL4275362 | 0.81 | PIM1 (0.41) | PIM1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL30940365 | 0.81 | PIM1 (0.41) | PIM1ALDH1A1KDM4EGAATSHR | |
| SCHEMBL4274421 | 0.80 | APP (0.43) | PIM1RAB9A | |
| SCHEMBL5780141 | 0.79 | MRGPRX4 (0.49) | NCEH1ALDH1A1KDM4EGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-3515887-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588891-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | PIM1 1496/4885P4HB 2363/4885NCEH1 4229/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | PIM1 1496/4885P4HB 2363/4885NCEH1 4229/4885 |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | PIM1 1496/4885P4HB 2363/4885NCEH1 4229/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | PIM1 1496/4885P4HB 2363/4885NCEH1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.